BioToxTech Co

BioToxTech Co FCF per Share

The Free Cash Flow per Share of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 303.02 KRW. In the previous year, Free Cash Flow per Share was -653.75 KRW — a change of -146.35% (higher).

FCF per Share

303.02KRW

YoY

-146.35%

Last updated:

Free Cash Flow per Share of BioToxTech Co is 2025 303.02 KRW. Free Cash Flow per Share of BioToxTech Co was 2024 -653.75 KRW. It decreases by -146.35% higher compared to the previous year.

The BioToxTech Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
51.10 KRW
Jan 1, 2019
68.43 KRW
Jan 1, 2020
219.99 KRW
Jan 1, 2021
-225.17 KRW
Jan 1, 2022
-2,208.25 KRW
Jan 1, 2023
-1,453.22 KRW
Jan 1, 2024
-653.75 KRW
Jan 1, 2025
303.02 KRW
The BioToxTech Co FCF per Share history
YEARFCF per ShareYoY
303.02KRW-146.35%
-653.75KRW-55.01%
-1,453.22KRW-34.19%
-2,208.25KRW+880.71%
-225.17KRW-202.35%
219.99KRW+221.50%
68.43KRW+33.91%
51.10KRW-71.71%
180.65KRW-45.21%
329.69KRW-470.15%
-89.07KRW-44.92%
-161.72KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Free Cash Flow per Share of BioToxTech Co is 303.02 KRW in 2025.

Free Cash Flow per Share of BioToxTech Co changed from -653.75 KRW to 303.02 KRW, representing a -146.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioToxTech Co

All Key Metrics — BioToxTech Co